Cantor Fitzgerald Brokers Cut Earnings Estimates for Metsera

Key Points

• Cantor Fitzgerald downgraded Metsera Inc.'s FY2025 earnings per share estimate to ($3.48), slightly lower than their previous forecast.
• Guggenheim raised Metsera's price target from $56.00 to $62.00 and maintained a "buy" rating, while Wells Fargo set an "overweight" rating with a $65.00 price objective.
• Metsera reported quarterly earnings of ($0.66) per share and has seen significant interest from institutional investors, with several acquiring new stakes recently.

Metsera Inc. (NASDAQ:MTSR - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Metsera in a research report issued to clients and investors on Tuesday, July 29th. Cantor Fitzgerald analyst P. Agrawal now expects that the company will earn ($3.48) per share for the year, down from their prior estimate of ($3.45). Cantor Fitzgerald also issued estimates for Metsera's FY2026 earnings at ($3.95) EPS.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Other research analysts also recently issued research reports about the company. Guggenheim upped their target price on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company initiated coverage on Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Metsera currently has a consensus rating of "Buy" and an average price target of $55.00.

Metsera Stock Performance

Shares of MTSR stock traded up $1.90 during midday trading on Thursday, reaching $34.89. 2,061,470 shares of the stock were exchanged, compared to its average volume of 1,033,961. Metsera has a 1 year low of $12.30 and a 1 year high of $47.40. The company has a 50 day simple moving average of $32.59.

Institutional Trading of Metsera

Several hedge funds and other institutional investors have recently made changes to their positions in MTSR. Strs Ohio purchased a new stake in shares of Metsera in the 1st quarter worth approximately $76,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Metsera in the 2nd quarter worth approximately $122,000. New York State Common Retirement Fund purchased a new stake in shares of Metsera in the 1st quarter worth approximately $131,000. Corebridge Financial Inc. bought a new position in Metsera in the 1st quarter valued at approximately $206,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Metsera in the 1st quarter valued at approximately $248,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.